GlassScriptPhysician profile
Lauren Hardy
NPI 1306388822
$837.32
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.11 · 2023: $505 · 2024: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171.59 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.15 | 2023-2024 | Caplyta |
| Axsome Therapeutics, INC. | $83.01 | 2023 | Auvelity, Sunosi |
| Alkermes, INC. | $75.21 | 2023-2024 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $68.27 | 2023-2024 | Rexulti, Abilify Maintena |
| Noven Therapeutics, LLC | $59.67 | 2024 | Secuado, Xelstrym |
| Lundbeck LLC | $56.17 | 2023 | Rexulti, Brintellix |
| Idorsia Pharmaceuticals US INC | $48.79 | 2023-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $47.17 | 2023-2024 | Spravato |
| Neurocrine Biosciences, INC. | $43.89 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $37.62 | 2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.11 | 2021 | |
| Bausch Health US, LLC | $19.67 | 2023 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.